Avatrombopag (Doptelet)

Mechanism of action

Thrombopoietin receptor agonist

Diseases for which it is established

• Immune thrombocytopenia
• Thrombocytopenia in liver disease

History of changes in FDA indication

• 2018-05-21: Approved for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.

History of changes in EMA indication

• 2019-06-20: Initial authorization as Doptelet
• Uncertain date: Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
• Uncertain date: Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Also known as

• Code names: E-5501, YM-477, AKR-501
• Brand name: Doptelet